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Abstract
Background: There is paucity of data regarding duration of fecal excretion and viremia on sequential samples
from individual patients and its correlation with serum transaminases and antibody responses in patients with
acute hepatitis E. This prospective study was undertaken at a tertiary care center in Northern India over 15 months.
Only those patients of sporadic acute hepatitis E who were in their first week of illness and followed up weekly for
liver function tests, IgM anti HEV antibody and HEV RNA in sera and stool were included. HEV RNA was done by RT
- nPCR using two pairs of primers from RdRp region of ORF 1 of the HEV genome.
Results: Over a period of 15 months 60 patients met the inclusion criterion and were enrolled for the final
analysis. The mean age of the patients was 29.2 ± 8.92 years, there were 39 males. The positivity of IgM anti HEV
was 80% at diagnosis and 18.3% at 7th week, HEV RNA 85% at diagnosis and 6.6% at 7th week and fecal RNA 70%
at the time of diagnosis and 20% at 4th week. The maximum duration of viremia detected was 42 days and fecal
viral shedding was 28 days after the onset of illness.
Conclusion: Present study reported HEV RNA positivity in sera after normalization of transaminases. Fecal shedding
was not seen beyond normalization of transaminases. However, viremia lasted beyond normalization of
transaminases suggesting that liver injury is independent of viral replication.
Background
H e p a t i t i sEv i r u si st h ee t i o l o g i c a la g e n to fn o n - H A V
enterically transmitted hepatitis and major cause of
sporadic as well as epidemic hepatitis [1,2]. In Indian
subcontinent, it accounts for 30-60% of sporadic hepati-
tis [3,4]. One distinct feature of hepatitis E, compared
with other forms of viral hepatitis is its higher incidence
and severity in pregnant woman [5]. The overall mortal-
ity rate of hepatitis E is generally lower than 1% but it
can be as high as 20-25% among pregnant women [6].
Being a disease of developing countries a fair amount
of information has been generated from India. There is
paucity of data regarding duration of fecal excretion and
viremia on sequential multiple samples from individual
patients and its relationship with serum transaminases
and IgM antibody response. This information is vital for
understanding pathogenesis and transmission dynamics
of acute hepatitis E. The information is either from a
human volunteer who ingested HEV [7] or a study [8],
based predominantly on pooled data of single sample
from different patients during HEV epidemics. Data on
sequential samples obtained from individual patients is
scant.
Two studies with relatively less number of patients
have looked for viremia and fecal shedding at varying
but not at regular intervals, the samples were collected
as and when the patients attended the clinics but not at
a fixed schedule [9,10]. Only in a recent Chinese study,
small number of patients (n = 32) were tested for vire-
mia in a sequential manner but fecal shedding and IgM
and anti-HEV were not studied [11]. The present study
has been undertaken where patients with sporadic acute
viral hepatitis were prospectively evaluated for transami-
nases, HEV viremia, HEV fecal shedding, and IgM anti-
body in multiple series samples obtained from individual
patients at weekly interval. Also, these parameters of
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The present study was undertaken prospectively at a ter-
tiary care center in Rajasthan, India. The study period
extended from 1
st Jan 2007 to 31
st Jan 2008 over 13
months. The study was approved by the institutional
ethics committee and informed written consent was
taken from the patients. The diagnosis of acute hepatitis
E was made on the basis of clinical presentation, raised
transaminases and Bilirubin, and positive IgM anti HEV
antibody and/or HEV RNA in sera. Only those patients
of sporadic acute hepatitis E who were in their first
week of illness, followed up weekly for liver function
tests, IgM anti HEV antibody and HEV RNA for final
analysis and those were failing these criteria excluded
from the study. Patients with concomitant positive IgM
anti HAV, IgM anti HBc or anti HCV (i.e. dual infec-
tion) and patients with underlying alcoholic liver disease
were also excluded from the study.
Sample Collection and Handling
The patients were asked to follow up weekly intervals
after the first visit. At each visit clinical sign and symp-
toms were noted. All events were measured with refer-
ence to day of the first symptoms. Serum and stool
samples were collected, coded and stored at -80°C till
processing. The stool and serum samples were obtained
for subsequent two weeks after the clearance of virus
from serum and stool to avoid any error and confirm
the negativity.
Biochemical analyses that include serum Bilirubin,
ALT, AST and serum alkaline phosphatase was done at
each visit by automated analyzer in the central labora-
tory of the institute. Coded sera of patients and positive
and negative controls were tested for IgM anti- HEV
using commercially available kit (Globe diagnostic SRL,
Italy).
RT-PCR
Extracted RNA by GITC chloroform phenol method
with minor modification [12] was subjected for cDNA
synthesis. cDNA synthesis was carried out using MuLV
RT enzyme, reverse primer (20 pmol/ml), RNase out
(20 U/μl, Gibco BRL), 0.1 M DTT and 5 μl templates at
42°C for one hour. After cDNA synthesis PCR amplifi-
cation was carried out using the specific primers
selected from nonstructural ORF-1 region (Gene Bank
accession no. M-32400) [1]. The thermal cycling condi-
tions were initial denaturation 94°C for 5 minutes fol-
lowed by 30 cycles of denaturation for 30 seconds at
94°C, annealing for 30 seconds at 59°C and extension
for 30 seconds at 72°C, as well as final extension for
7 minutes at 72°C. The final PCR products were
checked out on 2% gel electrophoresis stained with ethi-
dium bromide (10 mg/ml) under UV transillminator.
Figure 1 depicts the agarose gel electrophoresis of HEV
specific 343 base pair amplified product.
Statistical Analysis
For data management and statistical analysis, SPSS-10
software (SPSS Inc., Chicago, IL)was used. Baseline
laboratory markers were expressed as mean values with
standard deviation. Difference between pregnant and
non-pregnant females with respect to various liver func-
tion tests, and duration of persistence of IgM anti-HEV,
HEV viremia and HEV fecal RNA was calculated using
the student t-test. P value of less than 0.05 was consid-
ered significant.
Results
Over a period of thirteen months there were 60 patients
met the inclusion criterion and were enrolled for the
final analysis rest were excluded from the study because
of lack of desired follow up. The mean age of the
patients was 29.2 ± 8.92 years (range: 11 to 54 years)
and there were 39 males and 21 females; there were 10
pregnant and 11 non-pregnant females. Five pregnant
females were in third trimester, four in second trimester
and one in first trimester. Three pregnant females devel-
oped acute liver failure, 3 developed miscarriages and 1
died (after completion of study in the 3
rd month of ill-
ness), all pregnant females with complicated diseases
were in the third trimester. Uncomplicated acute hepati-
tis E was seen in 44 patients and acute liver failure in
16 patients.
Figure 1 Agarose gel electrophoresis shows HEV specific 343
base pair amplified product M: 100 bp ladder of molecular
weight markers; lanes 1: positive control; lanes 2-6: five serum
specimens from patients with hepatitis E; lane 7: negative control
from saline.
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stool samples were studied for fecal RNA. The mean
levels of serum Bilirubin, AST, ALT and alkaline phos-
phate and their fall over days are shown in the table 1.
Diagnosis of acute hepatitis E
There were thirteen patients with negative IgM anti
HEV but positive HEV RNA. There were eight patients
with positive IgM anti HEV and negative HEV RNA at
presentation; rest 39 patients had positivity of both IgM
anti HEV and HEV RNA.
Positivity of various markers of HEV infection
The positivity of IgM anti HEV was 78.3% at diagnosis
and 18.3% at 7
th week, HEV RNA 86.7% at diagnosis
and 6.6% at 6
th week and fecal shedding of HEV RNA
70% at the time of diagnosis and 20% at 4
th week and in
5
th week all the samples were negative. Table 2 shows
the positivity of IgM anti HEV, serum HEV RNA and
fecal viral shedding over weeks. The first to disappear is
fecal shedding followed by HEV RNA and then IgM anti
HEV. The maximum duration of HEV viremia was
42 days, HEV fecal shedding 28 days and IgM anti HEV
49 days. Protracted viremia i.e. persistence of HEV RNA
beyond normalization of ALT was seen in 4 patients up
till day 42. Figure 2 and 3 show the results of HEV vire-
mia and fecal shedding respectively in all 60 patients fol-
lowed weekly over an interval of 7 weeks. If any of the
test was negative at a particular week, two more samples
were tested in subsequence two weeks to confirm
negativity.
Mean ALT activity was higher in sera collected 1-7
days and declined there after. This suggested that liver
injury is highest during initial stages of infection. HEV
RNA was detected in 86.7% sera collected during first
seven days of illness when the ALT level was maximum.
Clinical parameter and pregnancy
The maximum duration of viremia was 42 days and 36
days, fecal shedding 28 days and 19 days and IgM anti
HEV 46 days and 49 days in pregnant females and non-
pregnant patients respectively. Table 3 shows the
comparison of liver function tests, duration of persis-
tence of IgM anti HEV, HEV viremia and fecal HEV
shedding between pregnant and non-pregnant females.
The two group did not differ significantly except for
fecal shedding (P = 0.006), viremia (P = 0.016) and mor-
tality rate(P = 0.010) that was significantly higher in
pregnant females.
Discussion
Hepatitis E is an important etiological agent of epidemic
and sporadic hepatitis associated with high morbidity
and mortality in pregnant females. The pathogenesis
and rate of transmission of hepatitis is not very clear.
Information on the duration of IgM anti HEV, viremia
and fecal shedding is very important to understand the
transmission dynamics and pathogenesis of hepatitis E,
but related data are particularly limited.
Therefore, the present study explained IgM anti HEV,
viremia, fecal shedding and level of transminases in indi-
vidual patient with acute sporadic hepatitis E. we were
selected 60 patients who provided sequential samples
for the study. The serial samples obtained from the indi-
vidual patients were studied for IgM anti HEV and HEV
RNA in sera and fecal matter weekly till disappearance
of HEV. Two subsequent samples were tested to con-
firm persistent negativity for HEV RNA. This is in com-
parison to a recent study from China that studied serial
samples (at around 5 day interval) in patients with acute
Table 1 Weekly levels of various liver function tests
Days S. Bilirubin(mg/dL) S. AST(U/L) S. ALT(U/L) SAP(U/L)
0-7 7.02 ± 3.5 961.5 ± 575.8 1145.1 ± 773 773 ± 643.5
8-14 6.69 ± 3.32 750 ± 717.6 746.1 ± 677.1 599.8 ± 521
15-21 5.97 ± 5.34 153.9 ± 130.4 253.3 ± 237.6 424.2 ± 265.8
22-28 4.91 ± 4.37 111.8 ± 67.67 147.2 ± 119 444.8 ± 346.5
29-35 2.98 ± 2.76 56.17 ± 30 73.47 ± 69 333.3 ± 318.8
36-42 1.2 ± 1.03 43.5 ± 16.3 45.5 ± 18 298.7 ± 276.37
37-49 0.96 ± 0.64 40.1 ± 21.08 40.8 ± 10.8 271.4 ± 235.6
Data expressed as mean ± SD
Table 2 Positivity of IgM anti HEV, HEV RNA and fecal
viral shedding in serial samples of patients with acute
sporadic hepatitis E (N = 60)
Days
† IgM anti HEV HEV RNA in sera Fecal Viral shedding
1-7 48(78.3) 51(86.7) 42(70)
8-14 43(71.6) 44(73.3) 30(50)
15-21 40(66.6) 38(63.3) 24(40)
22-28 35(58.3) 25(41.6) 12(20)
29-35 30(50) 15(25) 0(0)
36-42 26(43.3) 4(6.6) 0(0)
43-49 11(18.3) 0(0) 0(0)
Data expressed as number (percentage) and Days after the onset of illness
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Page 5 of 7hepatitis E and looked for HEV viremia [11]. A study
explained 26 patients with acute sporadic hepatitis E,
the samples were collected as and when the patient
came in contact with the author’sf o rI g Ma n t iH E V ,
HEV viremia and fecal shedding [10]. Similar method of
sample collection was reported in another study [9].
Few studies based on a volunteer and single sample
from patients are also available [7,8].
In the present study diagnosis of acute hepatitis E was
b a s e do ne i t h e rI g Ma n t iH E Vo rH E V - R N Ap o s i t i v i t y .
Positivity of IgM anti HEV (78.3%) was less than the
positivity for HEV-RNA (86.7%) thus indicating that
HEV RNA may be slightly better indicator for ongoing
HEV infection and hence its diagnosis. Even though
HEV RNA was better than anti HEV for diagnosis of
acute hepatitis, it cannot be a better test in routine, as
RT-PCR is cumbersome and costly. However, in a set-
ting of acute hepatitis if routine viral markers are nega-
tive, HEV RT-PCR may be the next useful tool of
investigation.
In the present study 13/60 (21.6%) patients were posi-
tive for HEV- RNA but negative from week 1 onwards.
Possible explanation for its negativity could be i.) low
sensitivity of the ELISA test used [13] ii.) sequence var-
iation among different genotypes [14] and iii.) a poor
host immune response to HEV infection [15]. Some
patients were positive for IgM anti HEV but negative for
HEV-RNA (13.3%), reason behind that the viremia is
short lived and disappeared prior to development of
icterus or early in 1
st week of development of icterus
and the variation of nucleotide sequence in the primary
regions among different HEV strains could be as high as
28%, which may account for the difficulty in PCR ampli-
fication [14].
In present series IgM anti HEV, viremia and fecal
shedding could be detected up to 49 days, 42 days and
28 days respectively after onset of illness. We have
shown earlier IgM anti HEV was positive up to 45 days
[16] and in another Indian study IgM anti HEV was
positive up to 21-112 days after iceterus [10]. A study
from China on serial sample in 32 patients viremia was
detected till 35 days after the onset of illness and in
other group of randomly selected samples maximum
duration of viremia was noted 51 days after the onset of
illness [11]. In another study viremia was lasted for a
maximum period of 45 days after the onset of illness
[9]. In a human self inoculation study with hepatitis E
virus, viremia was detected to last for 16 days [7]. In
another were single serum samples from patients with
acute hepatitis E was collected, HEV-RNA was detected
in 7% and 91% of serum sample collected on days 0-3
and 8-11 respectively; however, only two of the 11
serum samples obtained during days 27-41 tested posi-
tive [8]. In an Indian study, fecal shedding was studied
in only 4 patients, at varying intervals and lasted 9, 10,
12 and 52 days [10]. Fecal shedding was detected less
frequently than viremia. This finding is similar to earlier
reports [8,10,17]. The reason for this remains unknown.
Therefore, the present and previous reports suggest that
detection of fecal viral shedding is a less desirable event
for diagnostic approach than detection of viremia.
Till now there have been limited data including the
present study that talks of protracted viremia. The con-
cept of protracted viremia was first given by Nanda et al
and reported four patients in whom viremia extended
beyond the normalization of ALT; they concluded that
these patients may act as short term reservoirs for pro-
pagation of sporadic hepatitis E [10]. However, how they
act as reservoir was not mentioned. Aggarwal R et al
reported 1 case as protracted viremia and there were 4
such cases in the present study [9]. Viremia that lasts
beyond normalization of transaminases may suggest that
liver injury is independent of viral replication. The exact
importance of this concept is not known.
In the present study the duration of viremia, fecal
shedding and mortality was significantly higher in preg-
nant females in comparison to non-pregnant females
but duration of persistence of IgM antibodies and other
Table 3 Comparison of various liver function tests and persistence of various markers of HEV infection in pregnant
and non-pregnant females
Pregnant females (N = 10) Non-Pregnant females (N = 11) P value
S. bilirubin(mg %) 8.84 ± 2.23 7.518 ± 4.72 0.44
S. AST (IU) 1156.4 ± 183.04 925.81 ± 527.86 0.20
S. ALT (IU) 1295.3 ± 877.95 1272.53 ± 831.88 0.95
S. ALP (IU) 956.6 ± 511.51 1103 ± 814.77 0.63
Viremia
† 36.1 ± 5.82 29.09 ± 5.87 0.016
Fecal shedding
† 18.4 ± 4.19 13.0 ± 3.72 0.006
IgM anti HEV
† 40.1 ± 5.80 39.90 ± 4.86 0.84
Mortality (no.) 2 0
All values given in mean ± SD
† Maximum duration of persistence in days
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Page 6 of 7liver function tests were not different. This data is not
available in the literature to the best of our literature
search. However, the number of patients in both the
groups was small and would need further research on
large number of patients to reach any statistical conclu-
sion. Whether the pregnant females contribute more to
maintain the pool of hepatitis E in the society also
needs further studies. The authors feel that viral load
may be an important factor determining the outcome of
acute hepatitis E in pregnancy as has been shown by a
recent Indian study [18].
Conclusion
This is the largest study that analyzed 60 patients of
acute sporadic hepatitis E prospectively for IgM anti
HEV, viremia and fecal shedding. HEV RNA was better
than IgM anti HEV for diagnosis of acute hepatitis; still
its routine use for diagnosis of acute hepatitis E is not
feasible except in patients with negative IgM anti HEV,
high level of suspicion and in research setting. It was
observed that viremia lasts for a longer period than fecal
shedding in most patients. Although fecal shedding was
not seen beyond normalization of transaminases. Vire-
mia lasted beyond normalization of transaminases in
some patients and this may suggest that liver injury is
independent of viral replication. Viremia and fecal shed-
ding did not last too long to be responsible for mainte-
nance of HEV virus in the environment. The present
s t u d ya l s op r o v i d e sd a t ao n pregnant females for the
first time and duration of viremia and fecal shedding
was significantly more than non-pregnant females.
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